|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POLR3E |
Gene summary for POLR3E |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POLR3E | Gene ID | 55718 |
| Gene name | RNA polymerase III subunit E | |
| Gene Alias | C37 | |
| Cytomap | 16p12.2 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9NVU0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55718 | POLR3E | LZE4T | Human | Esophagus | ESCC | 2.97e-06 | 1.28e-01 | 0.0811 |
| 55718 | POLR3E | LZE7T | Human | Esophagus | ESCC | 3.54e-03 | 3.04e-01 | 0.0667 |
| 55718 | POLR3E | LZE8T | Human | Esophagus | ESCC | 3.37e-05 | 1.28e-01 | 0.067 |
| 55718 | POLR3E | LZE24T | Human | Esophagus | ESCC | 7.94e-03 | 1.90e-01 | 0.0596 |
| 55718 | POLR3E | LZE21T | Human | Esophagus | ESCC | 1.63e-02 | 1.36e-01 | 0.0655 |
| 55718 | POLR3E | P1T-E | Human | Esophagus | ESCC | 5.93e-07 | 3.04e-01 | 0.0875 |
| 55718 | POLR3E | P2T-E | Human | Esophagus | ESCC | 3.97e-19 | 5.10e-01 | 0.1177 |
| 55718 | POLR3E | P4T-E | Human | Esophagus | ESCC | 1.27e-06 | 1.72e-01 | 0.1323 |
| 55718 | POLR3E | P5T-E | Human | Esophagus | ESCC | 2.44e-05 | 1.48e-01 | 0.1327 |
| 55718 | POLR3E | P8T-E | Human | Esophagus | ESCC | 3.40e-11 | 2.04e-01 | 0.0889 |
| 55718 | POLR3E | P9T-E | Human | Esophagus | ESCC | 2.06e-04 | 4.75e-02 | 0.1131 |
| 55718 | POLR3E | P10T-E | Human | Esophagus | ESCC | 1.83e-04 | 4.71e-02 | 0.116 |
| 55718 | POLR3E | P11T-E | Human | Esophagus | ESCC | 2.48e-05 | 2.13e-01 | 0.1426 |
| 55718 | POLR3E | P12T-E | Human | Esophagus | ESCC | 8.64e-17 | 3.11e-01 | 0.1122 |
| 55718 | POLR3E | P15T-E | Human | Esophagus | ESCC | 2.64e-12 | 2.36e-01 | 0.1149 |
| 55718 | POLR3E | P16T-E | Human | Esophagus | ESCC | 1.25e-11 | 2.77e-01 | 0.1153 |
| 55718 | POLR3E | P17T-E | Human | Esophagus | ESCC | 3.33e-06 | 3.34e-01 | 0.1278 |
| 55718 | POLR3E | P19T-E | Human | Esophagus | ESCC | 5.24e-06 | 3.40e-01 | 0.1662 |
| 55718 | POLR3E | P20T-E | Human | Esophagus | ESCC | 1.24e-15 | 4.13e-01 | 0.1124 |
| 55718 | POLR3E | P21T-E | Human | Esophagus | ESCC | 1.89e-09 | 1.73e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0302021 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa046234 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0302031 | Esophagus | ESCC | RNA polymerase | 28/4205 | 34/8465 | 8.19e-05 | 3.35e-04 | 1.71e-04 | 28 |
| hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa03020 | Liver | HCC | RNA polymerase | 24/4020 | 34/8465 | 5.40e-03 | 1.57e-02 | 8.75e-03 | 24 |
| hsa030201 | Liver | HCC | RNA polymerase | 24/4020 | 34/8465 | 5.40e-03 | 1.57e-02 | 8.75e-03 | 24 |
| hsa030204 | Oral cavity | OSCC | RNA polymerase | 25/3704 | 34/8465 | 4.12e-04 | 1.27e-03 | 6.45e-04 | 25 |
| hsa04623 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
| hsa0302011 | Oral cavity | OSCC | RNA polymerase | 25/3704 | 34/8465 | 4.12e-04 | 1.27e-03 | 6.45e-04 | 25 |
| hsa046231 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POLR3E | SNV | Missense_Mutation | rs756072532 | c.1504N>T | p.Val502Leu | p.V502L | Q9NVU0 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AC-A7VC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POLR3E | SNV | Missense_Mutation | c.617T>G | p.Val206Gly | p.V206G | Q9NVU0 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| POLR3E | deletion | Frame_Shift_Del | novel | c.723delA | p.Ser243ValfsTer4 | p.S243Vfs*4 | Q9NVU0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| POLR3E | SNV | Missense_Mutation | novel | c.1379G>A | p.Arg460Gln | p.R460Q | Q9NVU0 | protein_coding | deleterious(0.02) | probably_damaging(0.948) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| POLR3E | SNV | Missense_Mutation | c.1049N>T | p.Cys350Phe | p.C350F | Q9NVU0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1ML-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| POLR3E | SNV | Missense_Mutation | novel | c.1510G>A | p.Glu504Lys | p.E504K | Q9NVU0 | protein_coding | tolerated(0.64) | benign(0.265) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| POLR3E | SNV | Missense_Mutation | rs368901417 | c.1840N>A | p.Ala614Thr | p.A614T | Q9NVU0 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| POLR3E | SNV | Missense_Mutation | novel | c.57N>T | p.Lys19Asn | p.K19N | Q9NVU0 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| POLR3E | SNV | Missense_Mutation | rs748039763 | c.1469C>T | p.Ala490Val | p.A490V | Q9NVU0 | protein_coding | tolerated(0.25) | benign(0.015) | TCGA-A6-6140-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | SD |
| POLR3E | SNV | Missense_Mutation | c.1966A>T | p.Ile656Phe | p.I656F | Q9NVU0 | protein_coding | deleterious(0.04) | benign(0.163) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |